On-going immunotherapy clinical trials

Treatment typePhaseTargetNAdditional therapyStageIdentifier
Chimeric antibodyI,IIEnsituximab116NoneMetastaticNCT01040000a
DNA vaccineIVEGFR-272NoneMetastaticNCT01486329a
Fungal vector vaccineIIRAS176GemcitabineResectedNCT00300950a
Viral vector vaccineISmall Pox Virus36NoneMetastaticNCT00574977a
Allogeneic vaccineICEA48GM-CSFMetastaticNCT00028496a
IDonor Lymphocyte37NoneMetastaticNCT00161187a
IDendritic cells12Poly-ICLCUnresectableNCT01677962
IIGM-CSF60Cetuximab + CyclophosphamideMetastaticNCT00305760a
IIGVAX56NoneMetastaticNCT00389610
IIGVAX87CyclophosphamideResectableNCT0072744
IIGVAX19Cyclophosphamide, Radiation, FOLFIRINOXResectedNCT01595321
IIGVAX +/- Mesothelin93CyclophosphamideMetastaticNCT01417000
IIGVAX +/- Mesothelin240Gemcitabine, Capecitabine, 5-FU, Irinotecan, Erlotinib or CyclophosphamideMetastaticNCT02004262
IIIFN-α + GM-CSF14CyclophosphamideMetastaticNCT00002773a
IIIVirulizin400Gemcitabine +/- 5-FUMetastaticNCT00040092a
Autologous vaccineICEA24NoneMetastaticNCT00004604a
ICEA14NoneMetastaticNCT00027534a
ICEA24Denileukin DiftitoxMetastaticNCT00128622a
IICEA48IL-2MetastaticNCT01723306
IDendritic Cells2Gemcitabine + Stereotactic RadiosurgeryMetastaticNCT00547144a
IIKLH35RadiationMetastaticNCT00868114
ImmunotherapyIB7-H393noneAllNCT01391143
ICD4010Gemcitabine + nab-paclitaxelMetastaticNCT02588443
ICD4010GemcitabineresectedNCT01456585a
IICTLA-482NoneMetastaticNCT00112580a
ICTLA-437GemcitabineMetastaticNCT00556023a
ICTLA-428GemcitabineMetastaticNCT01473940
IICTLA-4 + GVAX92FOLFIRINOXMetastaticNCT01896869
IIIDO98Gemcitabine + nab-paclitaxelmetastaticNCT02077881
IIL-1-Ra13FOLFIRINOXMetastaticNCT02021422
I/IIPD-156Capecitabine + RadiationResectable and Borderline ResectableNCT02305186
IPD-L11038noneAllNCT01693562
Peptide vaccineI,IIAlpha (1, 3) galactosyltransferase7NoneMetastaticNCT00255827a
IIIAlpha (1, 3) galactosyltransferase280FOLFIRINOXLocally AdvancedNCT01836432
IIIAlpha (1,3) galactosyltransferase722Gemcitabine, 5-FU, radiationResectedNCT01072981
I,IICEA28NoneMetastaticNCT00529984a
ICEA + MUC118NoneUnresectableNCT00669734
IhCG-β36NoneMetastaticNCT00648102a
IhCG-β48NoneMetastaticNCT00709462a
IHeat Shock Protein16NoneResectedNCT00003025a
I/IIHedgehog122GemcitabineMetastaticNCT01130142a
IHedgehog21FOLFIRINOXUnresectableNCT01383538
IMUC125NoneResected or Locally AdvancedNCT00008099a
I/IIMUC5AC90Gemcitabine + nab-paclitaxelUnresectableNCT01834235
IP5312NoneUnresectableNCT01191684a
IIP53 + RAS70IL-2MetastaticNCT00019084a
IRAS7NoneMetastaticNCT00006387a
IRAS33NoneMetastaticNCT00019006a
IIITelomerase1110Capecitabine + GemcitabineMetastaticNCT00425360a
ITGF-β168GemcitabineResectable and unresectableNCT01373164
ITrophoblast glycoprotein44NoneMetastaticNCT00056537a
I/IIVEGF17GemcitabineUnresectableNCT00655785a
IVEGFR-221GemcitabineMetastaticNCT00622622a

5-FU 5-flurouracil, CEA Carcinoembryonic antigen, CTLA-4 Cytotoxic T-lymphocyte associated protein-4, FOLFIRINOX folinic acid, fluorouracil, irinotecan, oxaliplatin, GM-CSF granulocyte macrophage colony stimulating factor, hCG Human chorionic gonadotropin, IDO indoleamine 2,3-dioxygenase, IFN interferon, IL-2 interleukin-2, KLH keyhole limpet hemocyanin, MUC mucin, N number, PD programmed death, PD-L programmed death ligand, Poly-ICLC carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA, TGF Transforming growth factor, VEGF Vascular endothelial growth factor, VEGF-R Vascular endothelial growth factor receptor

aStudy listed as complete but results not published